Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: Rifampicin
Drug: Isoniazid
Drug: Pyrazinamide
Drug: Kanamycin
Drug: Moxifloxacin

First Posted Date: 2009-01-01

Last Posted Date: 2019-12-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 19

Registration Number: NCT00816426

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Pusan National Unversity Hospital (PNUH), Busan, Korea, Republic of
🇰🇷
National Medical Center, Seoul, Korea, Republic of

Study of Daily Rifapentine for Pulmonary Tuberculosis

Phase 2

Completed

Conditions: Tuberculosis

Interventions: Drug: Rifapentine 450
Drug: Rifapentine 600
Drug: Rifampin

First Posted Date: 2008-12-25

Last Posted Date: 2018-02-06

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 153

Registration Number: NCT00814671

Locations: 🇿🇦
Universiy of Cape Town Lung Institute, Cape Town, Western Cape, South Africa

Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers

Phase 1

Completed

Conditions: Pharmacokinetics of YM178

Interventions: Drug: mirabegron
Drug: rifampin

First Posted Date: 2008-10-21

Last Posted Date: 2013-07-03

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 24

Registration Number: NCT00776516

Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis

Phase 2

Completed

Conditions: Tuberculosis

Interventions: Drug: Rifampicin in higher doses

First Posted Date: 2008-09-26

Last Posted Date: 2013-09-09

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 150

Registration Number: NCT00760149

Locations: 🇹🇿
Kibong'oto National Tuberculosis Hospital, Sanya Juu, Kilimanjaro, Tanzania

TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.

Phase 1

Completed

Conditions: Hepatitis C
HCV
Tuberculosis
Rifampin
Pharmacokinetics

Interventions: Drug: TMC435350
Drug: Rifampin
Drug: TMC435350+rifampin

First Posted Date: 2008-08-26

Last Posted Date: 2013-04-18

Lead Sponsor: Tibotec Pharmaceuticals, Ireland

Target Recruit Count: 21

Registration Number: NCT00741169

A Pilot Study of Inflammatory Markers in Alzheimer's Disease

Phase 3

Conditions: Alzheimer's Disease

Interventions: Drug: rifampin
Drug: doxycycline
Drug: placebo

First Posted Date: 2008-07-15

Last Posted Date: 2009-02-04

Lead Sponsor: McMaster University

Target Recruit Count: 21

Registration Number: NCT00715858

Locations: 🇨🇦
St.Peter's Hospital, Hamilton, Ontario, Canada

Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole Plus Rifampicin With a Regimen of Linezolid in the Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection

Phase 4

Completed

Conditions: MRSA Infection

Interventions: Drug: Linezolid
Drug: trimethoprim-sulfamethoxazole (TMP-SMX)
Drug: Rifampicin

First Posted Date: 2008-07-09

Last Posted Date: 2014-08-05

Lead Sponsor: University Hospital, Geneva

Target Recruit Count: 150

Registration Number: NCT00711854

Locations: 🇨🇭
Geneva University Hospitals, Geneva, Switzerland

TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment

Phase 2

Completed

Conditions: Pulmonary Tuberculosis

Interventions: Drug: rifapentine
Drug: rifampin

First Posted Date: 2008-06-10

Last Posted Date: 2014-05-08

Lead Sponsor: Centers for Disease Control and Prevention

Target Recruit Count: 865

Registration Number: NCT00694629

Locations: 🇺🇸
Washington DC Veterans Administration Medical Center, Washington DC, District of Columbia, United States
🇪🇸
Agencia de Salut Publica, Barcelona, Spain
🇺🇸
University of North Texas Health Science Center, Fort Worth, Texas, United States

and more 26 locations

Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions

Phase 1

Completed

Conditions: Adverse Drug Interactions

Interventions: Dietary Supplement: sulforaphane plus rifampicin
Drug: Rifampicin
Dietary Supplement: sulforaphane alone

First Posted Date: 2008-02-22

Last Posted Date: 2019-09-06

Lead Sponsor: University of Washington

Target Recruit Count: 29

Registration Number: NCT00621309

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
UW General Clinical Research Center, Seattle, Washington, United States

Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients

Phase 4

Conditions: HIV Infections
Tuberculosis

Interventions: Drug: Lumefantrine-artemether and nevirapine
Drug: lumefantrine-artemether and efavirenz
Drug: Lumefantrine-artemether and rifampicin

First Posted Date: 2008-02-21

Last Posted Date: 2010-12-06

Lead Sponsor: Makerere University

Target Recruit Count: 90

Registration Number: NCT00620438

Locations: 🇺🇬
Infectious Diseases Institute, Makerere University, Kampala, Uganda

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy